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Summary
Background WHO 2013 guidelines recommend universal treatment for HIV-infected children younger than 5 years. 
No paediatric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in ﬁ rst-line antiretroviral 
therapy (ART) in Africa, where most HIV-infected children live. We aimed to compare stavudine, zidovudine, or 
abacavir as dual or triple ﬁ xed-dose-combination paediatric tablets with lamivudine and nevirapine or efavirenz.
Methods In this open-label, parallel-group, randomised trial (CHAPAS-3), we enrolled children from one centre in 
Zambia and three in Uganda who were previously untreated (ART naive) or on stavudine for more than 2 years with 
viral load less than 50 copies per mL (ART experienced). Computer-generated randomisation tables were incorporated 
securely within the database. The primary endpoint was grade 2–4 clinical or grade 3/4 laboratory adverse events. 
Analysis was intention to treat. This trial is registered with the ISRCTN Registry number, 69078957.
Findings Between Nov 8, 2010, and Dec 28, 2011, 480 children were randomised: 156 to stavudine, 159 to zidovudine, 
and 165 to abacavir. After two were excluded due to randomisation error, 156 children were analysed in the stavudine 
group, 158 in the zidovudine group, and 164 in the abacavir group, and followed for median 2·3 years (5% lost to 
follow-up). 365 (76%) were ART naive (median age 2·6 years vs 6·2 years in ART experienced). 917 grade 2–4 clinical 
or grade 3/4 laboratory adverse events (835 clinical [634 grade 2]; 40 laboratory) occurred in 104 (67%) children on 
stavudine, 103 (65%) on zidovudine, and 105 (64%), on abacavir (p=0·63; zidovudine vs stavudine: hazard ratio [HR] 
0·99 [95% CI 0·75–1·29]; abacavir vs stavudine: HR 0·88 [0·67–1·15]). At 48 weeks, 98 (85%), 81 (80%) and 95 (81%) 
ART-naive children in the stavudine, zidovudine, and abacavir groups, respectively, had viral load less than 400 copies 
per mL (p=0·58); most ART-experienced children maintained suppression (p=1·00).
Interpretation All NRTIs had low toxicity and good clinical, immunological, and virological responses. Clinical and 
subclinical lipodystrophy was not noted in those younger than 5 years and anaemia was no more frequent with 
zidovudine than with the other drugs. Absence of hypersensitivity reactions, superior resistance proﬁ le and once-
daily dosing favours abacavir for African children, supporting WHO 2013 guidelines.
Funding European Developing Countries Clinical Trials Partnership.
Copyright Copyright © Walker et al. Open Access article distributed under the terms of CC BY.
Introduction
In 2014, 91% of 3·2 million HIV-infected children lived 
in sub-Saharan Africa, but less than 25% of those 
needing antiretroviral therapy (ART) were receiving it.1 
Low-cost, scored, dispersible ﬁ xed-dose combination 
(FDC) paediatric tablets of stavudine plus lamivudine 
plus nevirapine in child-appropriate drug ratios2 drove 
initial ART roll-out to African children, replacing 
separate syrups, which are costly for programmes and 
diﬃ  cult for carers to transport and administer.3 
However, stavudine was discouraged in 20104 and 20135 
WHO guidelines because of high lipodystrophy rates in 
adults and adolescents. In children, stavudine-
associated toxicity has mainly been noted with higher 
doses than those recommended by WHO and in older 
children.6–8
Alternative nucleoside reverse-transcriptase inhibitors 
(NRTIs) for children younger than 12 years are abacavir 
or zidovudine. Tenofovir is not licensed for those younger 
than 2 years and is not recommended by WHO5 in those 
younger than 10 years, primarily because of concerns 
regarding long-term eﬀ ects on bone metabolism and 
renal function in growing children,9 although more data 
are needed. Zidovudine is associated with anaemia, 
which is of particular concern in malnourished children 
in endemic malaria areas where underlying anaemia is 
prevalent. Abacavir is associated with hypersensitivity 
reactions, although these are rare in Africa10 because of a 
lower risk-allele prevalence.11 However, two South African 
cohorts recently reported lower virological suppression 
with abacavir than with stavudine,12,13 and abacavir is also 
the most costly NRTI.14 Therefore, whether stavudine, 
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given at the WHO recommended doses, should remain 
an option for young children was unclear.
Since 2003, changes in NRTIs recommended by WHO 
for children, followed by changes in national guidelines 
and clinical practice, have occurred with little evidence 
and no new randomised trials. Therefore, in 2010, when 
most African children were receiving stavudine-based 
ART, we aimed to compare stavudine, zidovudine, or 
abacavir ﬁ xed-dose combinations for ﬁ rst-line ART.
Methods
Study design and participants
In this open-label, parallel-group, randomised controlled 
trial (CHAPAS-3), we enrolled conﬁ rmed HIV-infected 
children from Zambia and Uganda—centres were from 
Zambia—the University Teaching Hospital (UTH), Lusaka; 
and from Uganda Baylor-Uganda Centre of Excellence, 
Kampala, and Joint Clinical Research Centre (JCRC), 
Kampala and Gulu (satellite site)—aged 1 month to 13 years 
if they were either previously untreated and met WHO 
20104 criteria for ART (ART naive; <5 years in Uganda), or 
on stavudine-containing ﬁ rst-line (non-nucleoside reverse-
transcriptase inhibitors [NNRTI]-containing) ART for 
2 years or more with screening viral load less than 50 copies 
per mL and stable CD4 and/or CD4 cell % (ART-experi-
enced; no signs of lipodystrophy; see appendix p 2 for 
additional eligibility criteria). All children were already on 
or initiated co-trimoxazole prophylaxis at enrolment (or 
dapsone if unable to take co-trimoxazole). Caregivers gave 
written consent; older children aware of their HIV status 
also gave assent or consent following national guidelines. 
The trial was approved by Research Ethics Committees in 
Zambia, Uganda, and the UK.
Randomisation and masking
Children were randomly assigned (1:1:1) to receive open-
label stavudine, zidovudine, or abacavir, together with 
lamivudine and either nevirapine or efavirenz (at treating 
paediatrician’s discretion: all <3 years received nevirapine). 
Randomisation was stratiﬁ ed by age (younger than 5 years 
vs 5 years or older), previous ART (naive vs experienced), 
NNRTI (nevirapine vs efavirenz), and clinical centre. A 
computer-generated sequential randomisation list, using 
the urn probability method15 was prepared by the trial 
statistician and incorporated securely into the trial 
database at each centre. The list was concealed until 
allocation, which occurred after eligibility was conﬁ rmed 
by local centre staﬀ , who then did the randomisation.
Procedures
Scored dispersible ﬁ xed-dose combinations of abacavir 
plus lamivudine, zidovudine plus lamivudine, zidovudine 
Research in context
Evidence before this study
We searched PubMed up to April 27, 2015, using the keywords 
“HIV”, “child*”, (“stavudine” or “zidovudine” or “abacavir”), not 
“prevent*” (to exclude a large number of studies looking at 
zidovudine to prevent mother-to-child HIV transmission), dated 
after Jan 1, 1996, (when combination ART was introduced). The 
most relevant nucleoside reverse-transcriptase inhibitors (NRTIs) 
for treating HIV-infected children when the study started were 
abacavir, zidovudine, and stavudine; didanosine and tenofovir 
were not used because of toxicity (genuine or a potential 
concern, respectively). The WHO conducts systematic reviews as 
part of guideline development. No existing systematic reviews of 
randomised controlled trials comparing these NRTIs head-to-
head in HIV-infected children were identiﬁ ed in 2010 or 2013, 
with only one randomised trial directly comparing abacavir and 
zidovudine in 128 European children, which identﬁ ed that 
abacavir was virologically superior to zidovudine over 5 years 
follow-up. Recommendations for preferential ordering of 
zidovudine, abacavir, then stavudine in 2010, and abacavir, 
zidovudine, then stavudine in 2013, were therefore based 
primarily on expert opinion balancing toxicity (estimated from 
observational studies and randomised trials not containing 
head-to-head comparisons), cost (greater with abacavir), and 
practicality (particularly availability as part of ﬁ xed-dose-
combination tablets and once-daily dosing); and, in 2013, also 
evidence on accumulation of diﬀ erent resistance mutations with 
sequential use.
Added value of the study
This is the ﬁ rst randomised controlled trial in African children, 
conducting a head-to-head comparison of the three most 
relevant NRTIs for paediatric treatment, coformulated in 
NNRTI/NRTI generic ﬁ xed-dose-combination paediatric 
tablets and dosed with WHO drug ratios and weight bands. 
We identiﬁ ed no major diﬀ erences between the NRTIs in 
adverse events, toxicity, clinical, immunological, or viral load 
endpoints, but did ﬁ nd higher drug susceptibility to relevant 
second-line NRTIs if abacavir was used ﬁ rst-line, thus 
providing evidence to support the WHO 2013 
recommendation for its use as the preferred ﬁ rst-line NRTI 
for children. Use of abacavir also enables a once-daily ART 
regimen to be constructed for children, in line with adults.
Implications of the available evidence
Excellent outcomes were obtained on all regimens, 
showing the importance of widening treatment access 
for HIV-infected children worldwide. Eﬀ orts need to be made 
to provide abacavir-based combinations where this is 
possible; but there is no need to move children who are stable 
on zidovudine-based regimens to abacavir. Further 
research should investigate the potential for once-daily triple 
abacavir-based ﬁ xed-dose combinations with efavirenz or 
dolutegravir to further simplify and improve durability of 
ﬁ rst-line ART for children who will need treatment for much 
longer than adults.
See Online for appendix
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plus lamivudine plus nevirapine, stavudine plus 
lamivudine, and stavudine plus lamivudine plus 
nevirapine as so-called baby and junior tablets (Cipla 
Pharmaceuticals, Mumbai, India) were prescribed 
following WHO weight bands5 (stavudine at lower doses 
than previous studies6–8 at 2–4 mg/kg [<10 kg] and at 
1·4–2·4 mg/kg [>10 kg] daily). Efavirenz (600 mg double-
scored, allowing daily doses of 200 mg, 300 mg, 400 mg, 
500 mg, and 600 mg) and nevirapine (200 mg scored) 
were also supplied for children taking dual NRTI ﬁ xed-
dose combinations.
Children exited the trial from Oct 30, 2013, to Jan 23, 
2014, after a minimum of 96 weeks follow-up. At nurse 
(6-weekly) and doctor (12-weekly) visits, children were 
examined, medical history was recorded, adherence was 
assessed (self-report), and ART was dispensed. At weeks 
6, 12, 24, and then 24-weekly, ﬁ ve skinfold thicknesses 
(triceps, biceps, sub-scapular, supra-iliac, and mid-
thigh) and ﬁ ve body circumferences (waist, hip, mid-
thigh, mid-upper-arm [MUAC], and torso) were 
measured to assess lipodystrophy (mean of three 
measure ments); haematology, biochemistry, and CD4 
tests were done (results available to clinicians); and 
plasma was stored for retrospective viral load and 
resistance testing (results not available to clinicians in 
real time). Substitutions for toxicity and switches to 
second-line for failure were at the treating physician’s 
discretion, following WHO guidelines.5
Outcomes
The primary outcome was grade 2 or greater clinical 
adverse events, conﬁ rmed grade 3 laboratory adverse 
events, or any grade 4 laboratory adverse events16 
(neutrophils17 ). Clinical primary endpoints were 
adjudicated against protocol-deﬁ ned criteria by an 
endpoint review committee (ERC), masked to allocation, 
and were also adjudicated for relation to antiretroviral 
drugs, without knowing the speciﬁ c ART received. 
Secondary toxicity outcomes were speciﬁ c subsets of the 
primary endpoints (anaemia, neutropenia, lipodystrophy 
or lipoatrophy, hyper sensitivity [also including grade 1 
events]), serious adverse events, ART-modifying toxicity 
(any grade), grade 3/4 adverse events possibly, probably, 
or deﬁ nitely related to zidovudine or abacavir or 
stavudine, and changes in skinfold-thicknesses-for-age 
and body-circumference-for-age. Secondary eﬃ  cacy 
outcomes were viral load suppression, clinical disease 
progression, change in weight-for-age, height-for-age, 
and CD4 and ART adherence. Laboratory measures, 
including viral load, were assayed blind to randomisation. 
HIV-1 viral load was assayed with the Roche COBAS 
Ampliprep/Taqman version 2.0 in both Uganda (Joint 
Clinical Research Centre [JCRC]) and Zambia (Centre for 
Infectious Disease Research in Zambia [CIDRZ]). 
Because of small stored sample volumes, most samples 
were run with a 1/5 dilution with Basematrix 53, giving a 
lower limit of detection of 100 copies per mL. Drug 
resistance genotyping was done with either in-house 
primers (JCRC) or primers from Inqaba Biotec (CIDRZ), 
with both laboratories using an automated ABI 3730xl 
sequencer.
Statistical analysis
Recruiting 470 children gave 85% power to detect a 
reduction from 20% to 10% in the cumulative incidence 
of the primary endpoint across the three randomised 
groups (two-sided α=0·05; appendix p 2). Interim data 
were reviewed by an independent data monitoring 
committee (two meetings, approximately annually) using 
the Haybittle-Peto criterion (p<0·001). Randomised 
groups were compared with intention-to-treat analysis 
with log-rank tests for time-to-event outcomes, exact tests 
for binary outcomes, and generalised estimating 
equations with independent working correlation for 
global tests of repeated measures. Analyses were 
stratiﬁ ed by age group, naive or experienced, and NNRTI, 
but not by clinical centre because this was not expected to 
aﬀ ect outcome (randomisation was stratiﬁ ed by centre 
for practical reasons; see appendix p 3 for more detail). 
Data were analysed with Stata version 13.1.
This trial is registered with the ISRCTN Registry 
number, 69078957.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Nov 8, 2010, and Dec 28, 2011, 480 children were 
randomly assigned: 156 to stavudine, 159 to zidovudine, 
and 165 to abacavir. After two were excluded due to 
randomisation error, 156 children were analysed in the 
stavudine group, 158 in the zidovudine group, and 164 in 
the abacavir group. More children were ART naive 
(365 [76%]) than ART experienced (113 [24%]); more were 
younger than 5 years (337 [71%]); and consequently more 
received nevirapine (353 [74%]) than efavirenz (more 
similar percentages >3 years received nevirapine (155 [57%]) 
and efavirenz (116 [43%]; table 1).
Baseline characteristics were well balanced between 
randomised groups (table 1). ART-naive children were 
substantially younger than ART-experienced children 
(median 2·6 years [IQR 1·6–4·0] vs 6·2 years [5·5–7·2], 
with lower CD4% (median 20% [IQR 13–25] vs 35% 
[30–39]). Median retrospectively assayed viral load was 
270 670 copies per mL in ART-naive children (79% 
>100 000 copies per mL), with three (1%) conﬁ rmed less 
than 100 copies per mL at both screening and enrolment 
(carers reported no previous ART, no previous samples 
available). ART-experienced children (all <50 copies 
per mL) had taken stavudine-based ART for median 
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3·5 years (IQR 2·6–4·2). The mother or child had 
received nevirapine or NRTIs for prevention of mother-
to-child transmission in 56 (15%) ART-naive and nine 
(8%) ART-experienced children (table 1).
Median follow-up was 2·3 years among children 
completing the study (range 1·8–3·1; total 1057 child-
years). 25 (5%) children were lost (last seen before 
October, 2013), including eight (2%) who withdrew 
consent. 8967 (98%) of 9143 scheduled nurse visits were 
completed.
Initial ART followed randomisation for 473 (99%) 
children (ﬁ gure 1). 445 (93%) remained on their initial 
treatment throughout follow-up. 33 ﬁ rst-line ART 
changes occurred among 30 (6%) children: ten (6%) 
allocated stavudine, 16 (10%) allocated zidovudine, and 
four (2%) allocated abacavir (p=0·02). Nine changes 
Naive Experienced
Stavudine (n=123) Zidovudine (n=112) Abacavir (n=130) All (n=365) Stavudine (n=33) Zidovudine (n=46) Abacavir (n=34) All (n=113)
Centre UTH, Lusaka, 
Zambia
30 (24%) 25 (22%) 34 (26%) 89 (24%) 15 (45%) 22 (48%) 15 (44%) 52 (46%)
 Baylor, Kampala, 
Uganda
42 (34%) 36 (32%) 41 (32%) 119 (33%) 7 (21%) 8 (17%) 7 (21%) 22 (19%)
JCRC, Kampala, Uganda 34 (28%) 36 (32%) 32 (25%) 102 (28%) 11 (33%) 16 (35%) 12 (35%) 39 (35%)
JCRC, Gulu, Uganda 17 (14%) 15 (13%) 23 (18%) 55 (15%) 0 0 0 0
Age (years) 2·6
(1·6–4·1)
2·6
(1·7–3·9)
2·7
(1·7–4·0)
2·6
(1·6–4·0)
6·5
(5·9–7·3)
6·0
(5·5–7·2)
5·9
(5·4–7·2)
6·2
(5·5–7·2)
Sex
Male 66 (54%) 54 (48%) 67 (52%) 178 (49%) 23 (70%) 22 (48%) 14 (41%) 59 (52%)
Female 57 (46%) 58 (52%) 63 (48%) 187 (51%) 10 (30%) 24 (52%) 20 (59%) 54 (48%)
Z score
Weight-for-age –2·3 (1·8) –2·2 (1·6) –1·9 (1·6) –2·1 (1·6) –1·1 (0·7) –1·0 (1·2) –1·4 (1·0) –1·1 (1·0)
Height-for-age –2·5 (1·7) –2·6 (1·7) –2·3 (1·7) –2·5 (1·7) –1·6 (0·8) –1·4 (1·2) –1·8 (0·9) –1·6 (1·0)
Body-mass index-for-
age
–0·7 (1·6) –0·4 (1·4) –0·5 (1·5) –0·5 (1·5) –0·1 (0·8) –0·1 (1·0) –0·3 (0·9) –0·2 (0·9)
WHO stage*
1 17 (14%) 10 (9%) 14 (11%) 41 (11%) 8 (24%) 10 (22%) 7 (21%) 25 (22%)
2 45 (37%) 46 (41%) 48 (37%) 139 (38%) 8 (24%) 9 (20%) 7 (21%) 24 (21%)
3 50 (41%) 41 (37%) 56 (43%) 147 (40%) 8 (24%) 24 (52%) 11 (32%) 43 (38%)
4 11 (9%) 15 (13%) 12 (9%) 38 (10%) 9 (27%) 3 (7%) 9 (26%) 21 (19%)
Viral load (copies per mL)†
Log10 5·6 (0·7) 5·4 (0·8) 5·3 (0·8) 5·4 (0·8) <50 <50 <50 <50 
Absolute 328 320
(191 770–926 170)
252 390
(107 830–808 330)
217 540
(78 760–609 520)
270 670
(116 330–738 360)
<50 <50 <50 <50 
>100 000 copies per 
mL
100 (84%) 85 (79%) 95 (74%) 280 (79%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CD4 cell count
CD4% 19%
(12–23)
21%
(15–26)
19%
(11–24)
20%
(13–25)
35%
(28–39)
35%
(30–40)
35%
(31–39)
35%
(30–39)
Absolute CD4 865
(581– 1236)
925
(675–1434)
813
(490–1353)
893
(597–1299)
1143
(987–1414)
1164
(916–1641)
1362
(1072–1656)
1191
(962–1587)
Stavudine, years ·· ·· ·· ·· 3·0 (2·3–3·6) 3·9 (3·0–4·5) 3·5 (2·5–4·2) 3·5 (2·6–4·2)
Any pMTCT received by 
mother or child
15 (12%) 20 (18%) 21 (16%) 56 (15%) 3 (9%) 3 (7%) 3 (9%) 9 (8%)
Nevirapine‡ only 8 (7%) 12 (11%) 18 (14%) 38 (10%) 3 (9%) 3 (7%) 3 (9%) 9 (8%)
Nevirapine‡ and NRTI§ 4 (3%) 3 (3%) 2 (2%) 9 (2%) 0 0 0 0
NRTI only§ 3 (2%) 5 (4%) 1 (1%) 9 (2%) 0 0 0 0
Received nevirapine 
with randomised NRTIs 
in ART
87 (71%) 75 (67%) 90 (69%) 252 (69%) 29 (88%) 42 (91%) 30 (88%) 101 (89%)
Data are n (%), median (IQR), or mean (SD). UTH=University Teaching Hospital. JCRC=Joint Clinical Research Centre. pMTCT=prevention of mother-to-child transmission. NRTI=nucleoside reverse-transcriptase 
inhibitors. ART=antiretroviral treatment.*Derived from pre-trial WHO event history before and after ART initiation in ART experienced. †ART naive: four missing in stavudine group, four in zidovudine group, and 
two abacavir group due to samples not being stored. ‡Single-dose nevirapine to either mother or child or both, or less than 2 days nevirapine to the child (with or without single-dose nevirapine to the mother). 
§Zidovudine to the child or zidovudine (majority) or zidovudine plus lamivudine to the mother.
Table 1: Baseline characteristics
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(three stavudine, four zidovudine, and two abacavir) were 
nevirapine substitutions for rifampicin-based tuber-
culosis co-treatment, 14 were nevirapine or NRTI toxicity 
substitutions, and ten were mostly dispensing errors. 
Five children ([1%]; all ART-naive, one [1%] stavudine, 
two [1%] zidovudine, two [1%] abacavir; p=1·0) switched 
to second-line ART (two clinical, three immunological or 
virological failure). There was no evidence that self-
reported adherence (proportion reporting missing ART 
doses in the last 4 weeks) across visits through 96 weeks 
diﬀ ered between randomised groups (p=0·82).
917 grade 2–4 clinical or grade 3/4 laboratory adverse 
events (877 clinical; 40 laboratory) occurred in 312 children 
(104 [67%] children allocated stavudine, 103 [65%] 
children allocated zidovudine, and 105 [64%] children 
allocated abacavir; p=0·63; ﬁ gure 2, table 2; appendix 
p 7). Events were more common in younger ART-naive 
children than in ART-experienced children (ﬁ gure 2A), 
but there was no evidence of heterogeneity in diﬀ erences 
between randomised groups (p=0·41). 634 clinical events 
were grade 2 (481 non-serious respiratory tract infections); 
excluding grade 2 events gave similar results (p=0·48; 
ﬁ gure 2B). 199 serious adverse events occurred in 
132 (28%) children, with no diﬀ erence between 
randomised groups (p=0·46; table 2). Six (4%) children 
allocated stavudine, 12 (8%) allocated zidovudine, and 
ﬁ ve (3%) allocated abacavir had grade 3/4 adverse events 
judged by the ERC (masked to randomisation) to have at 
least a possible relation to one of the randomised NRTIs 
(p=0·10; table 2). No grade 3/4 adverse events or serious 
adverse events were judged deﬁ nitely or probably related 
to stavudine, zidovudine, or abacavir.
14 (3%) children modiﬁ ed ART for toxicity; with 
signiﬁ cantly more in the zidovudine group (p=0·03; 
table 2) where eight children substituted zidovudine with 
stavudine or abacavir for anaemia (n=4), neutropenia 
(n=3), or leucopenia (n=1). However, there was no 
evidence of diﬀ erences between groups in grade 3/4 
anaemia (p=0·42 overall; pairwise p>0·25), although 
more grade 3/4 neutropenia occurred in the zidovudine 
group (p=0·04 overall; zidovudine vs stavudine p=0·03, 
zidovudine vs abacavir p=0·06, stavudine vs abacavir 
p=0·79). Three children substituted ART (all nevirapine to 
lopinavir plus ritonavir) for hypersensitivity reactions (one 
grade 2, one grade 3, one grade 4 [Stevens-Johnson; 
recovered]; none on abacavir). Masked to NRTI received, 
the ERC adjudicated ﬁ ve stavudine, one zidovudine, and 
two abacavir primary endpoints as grade 2–4 hyper-
sensitivity reactions (p=0·21; table 2, supplementary 
tables 1 and 2; appendix p 7); however, neither child on 
abacavir stopped the drug with no adverse consequences. 
One additional grade 1 hypersensitivity reaction was 
reported in the abacavir group; this child also continued 
abacavir without adverse eﬀ ects.
Figure 1: Trial proﬁ le
ART=antiretroviral treatment. *Includes one not seen after randomisation. †One participant started stavudine and substituted zidovudine at 12 weeks, two started 
abacavir and did not change (both prescribing errors). ‡Two started zidovudine and did not change (one prescribing error and one child changed regimen to match 
twin sibling). 
634 screened
154 not randomised
151 met protocol exclusion criteria
59 WHO criteria for ART not met
28 on ART, viral load >50 copies per mL
26 laboratory abnormality
20 unwilling to attend
5 on acute tuberculosis treatment
4 were HIV negative
4 were aged <1 year and had received 
    perinatal ART
3 had acute opportunistic infection
2 on contraindicated medication
3 other reason
3 did not return480 randomised
156 assigned to stavudine 159 assigned to zidovudine
1 randomised in error (<3 years old 
on induction tuberculosis treatment)
165 assigned to abacavir
1 randomised in error (subsequently 
found to be HIV uninfected)
18 discontinued the trial
8 lost to follow-up*
3 withdrew consent
7 died
11 discontinued the trial
5 lost to follow-up
3 withdrew consent
3 died
15 discontinued the trial
4 lost to follow-up*
2 withdrew consent
9 died
156 included in intention-to-treat analysis 158 included in intention-to-treat analysis
3 did not start treatment as randomised†
164 included in intention-to-treat analysis
2 did not start treatment as randomised‡
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Two ART-experienced children substituted stavudine 
with abacavir after developing facial lipoatrophy (grade 2 
[boy, age 6 years, 2·5 years on stavudine]; grade 3 [boy, 
age 8 years, 5 years on stavudine]). Body circumference 
increased with time at all measured sites, as expected, 
while the ﬁ ve skinfold thicknesses decreased similarly in 
ART-naive and ART-experienced children (appendix p 12, 
19), with few diﬀ erences between randomised groups 
(appendix p 5). There was no evidence that randomised 
groups diﬀ ered in body circumference or skinfold 
thickness ratios or the sum of the four skinfolds (p>0·1; 
table 3), or in changes in total cholesterol, LDL, HDL, or 
triglycerides (p>0·4; appendix p 14).
Disease progression was rare and similar across 
randomised groups (p>0·3; table 2). All 19 deaths, and 
12 of the 14 WHO stage 3 or 4 events, occurred in ART-
naive children (seven pneumonia, three tuberculosis 
WHO stage 3/4 events). Nine of 19 deaths and ﬁ ve of 
14 WHO 3/4 events occurred less than 12 weeks after 
ART initiation, related to pre-enrolment disease severity. 
There was very little evidence of drug-related mortality 
(appendix p 15). Change in weight-for-age, height-for-
age, or body-mass index-for-age to 96 weeks did not diﬀ er 
signiﬁ cantly between groups (p>0·2).
Most ART-naive children achieved viral load less than 
400 copies per mL by 48 weeks (ﬁ gure 3A), with no 
diﬀ erences between randomised groups (p=0·58; 
ﬁ gure 3; appendix p 16). Viral load less than 400 copies 
per mL was maintained at 48 weeks by more than 96% 
ART-experienced children (p=1·0). Results were similar 
between groups at 96 weeks in ART-naive and ART-
experienced children (p>0·4), as was viral load 
suppression less than 100 copies per mL at 48 weeks and 
96 weeks (ﬁ gure 3B). Among ART-naive children, 
48-week suppression was better in those with viral load 
less than 100 000 copies per mL at enrolment (66 [93%] of 
71 vs 202 [80%] of 254), consistently across randomised 
groups with no evidence that any NRTI had superior 
performance in these strata (pinteraction=0·85). 48-week 
suppression was similar in ART-naive children aged 
3 years or older at enrolment receiving nevirapine 
(42 [89%] of 47) and efavirenz (88 [91%] of 97), also with 
no evidence of variation across randomised groups 
(pinteraction=0·25). There was also no evidence that 48-week 
viral load suppression in ART-naive children older than 
1 year varied by previous prevention of mother-to-child 
transmission exposure to nevirapine without NRTI cover 
(34 [79%] of 43) versus those who had not (219 [85%] of 
258; pinteraction=0·09). There was no evidence of diﬀ erential 
CD4% recovery across randomised groups (p=0·09; 
appendix p 16).
Resistance mutations were assayed in 58 (84%) of 
69 children with viral load greater than 500 copies per mL 
at 96 weeks (19 allocated stavudine, 22 allocated zidovudine, 
and 17 allocated abacavir; remaining samples failed). Seven 
children (ﬁ ve allocated stavudine, one allocated zidovudine, 
and one allocated abacavir) had no NNRTI or NRTI 
mutations. As expected, M184V and NNRTI mutations 
were common in all groups, thymidine-analogue mutations 
(TAMs) were common in stavudine and zidovudine groups 
(although TAM-1 41L/210W/215Y were only seen in the 
zidovudine group), and 74V/115F mutations were common 
in the abacavir group (appendix p 18). However, only one 
Figure 2: Primary endpoint (clinical adverse event grade 2 or higher, conﬁ rmed laboratory grade 3 adverse 
event, or any laboratory grade 4 adverse event; A) and grade 3 or 4 primary endpoint (B)
ART=antiretroviral treatment.
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K65R mutation was identiﬁ ed in the abacavir group. In the 
abacavir group, sensitivity to second-line NRTI options was 
100% for zidovudine and 94% for tenofovir. In the 
zidovudine and stavudine groups, sensitivity to tenofovir 
remained high (86% and 100%, respectively; p=0·22 across 
randomised NRTIs; appendix p 21), but, as expected, was 
Stavudine 
(n=156); 
N (%)
Zidovudine (n=157) Abacavir (n=164) Abacavir vs 
zidovudine; 
HR (95% CI)
N (%) HR vs stavudine 
(95% CI)
N (%) HR vs stavudine 
(95% CI)
p value*
Primary endpoint adverse event† 104 (67%) 103 (65%) 0·99 (0·75–1·29) 105 (64%) 0·88 (0·67–1·15) 0·63 0·89 (0·68–1·17)
Speciﬁ c subsets of primary endpoint 
adverse events
Anaemia, grade 3/4 5 (3%) 9 (6%) 1·93 (0·64–5·76) 6 (4%) 1·15 (0·35–3·78) 0·42 0·60 (0·21–1·69)
Anaemia, grade 4 5 (3%) 7 (4%) 1·45 (0·46–4·57) 3 (2%) 0·57 (0·14–2·38) 0·38 0·39 (0·10–1·52)
Neutropenia, grade 3/4 4 (3%) 12 (8%) 3·21 (1·03–9·98) 5 (3%) 1·21 (0·32–4·49) 0·04 0·38 (0·13–1·07)
Neutropenia, grade 4 3 (2%) 10 (6%) 3·55 (0·97–12·9) 4 (2%) 1·29 (0·29–5·75) 0·06 0·36 (0·11–1·16)
Hypersensitivity reaction‡ 5 (3%) 1 (0·6%) 0·22 (0·03–1·86) 2 (1%) 0·38 (0·07–1·95) 0·21 1·75 (0·16–19·3)
Lipodystrophy/lipoatrophy 2 (1%) 0 ·· 0 ·· 0·08 ··
Mitochondrial disease§ 1 (0·6%) 0 ·· 1 (0·6%) ·· 0·65 ··
Grade 3/4 adverse events¶ 46 (29%) 53 (34%) 1·24 (0·83–1·84) 51 (31%) 1·01 (0·68–1·50) 0·48 0·82 (0·56–1·20)
Grade 3/4 adverse events adjudicated 
as NRTI related||
6 (4%) 12 (8%) 2·12 (0·79–5·66) 5 (3%) 0·80 (0·25–2·63) 0·10 0·38 (0·13–1·08)
Serious adverse events 46 (29%) 44 (28%) 0·98 (0·65–1·48) 42 (26%) 0·78 (0·51–1·19) 0·46 0·80 (0·52–1·22)
Serious adverse events adjudicated as 
NRTI related||
8 (5%) 12 (12%) 1·50 (0·61–3·67) 6 (6%) 0·64 (0·22–1·85) 0·22 0·43 (0·16–1·14)
Toxicity causing ART modiﬁ cation** 4 (3%) 9 (6%) 2·24 (0·69–7·32) 1 (1%) 0·23 (0·03–2·09) 0·03 0·10 (0·01–0·83)
New WHO stage 3 or 4 event or death 9 (6%) 7 (4%) 0·84 (0·31–2·26) 13 (8%) 1·37 (0·58–2·30) 0·55 1·62 (0·65–4·07)
Death†† 7 (4%) 3 (2%) 0·48 (0·12–1·85) 9 (5%) 1·23 (0·46–3·29) 0·35 2·56 (0·69–9·45)
All HRs were stratiﬁ ed for randomisation stratiﬁ cation factors. No evidence of interaction between naive versus experienced strata on any outcome in table 2 (p>0·1; 
21 tests), except for serious adverse events (p=0·02; naive children with serious adverse events: 46 allocated stavudine, 40 allocated zidovudine, and 39 allocated abacavir; 
experienced children: none allocated stavudine, four allocated zidovudine, and three allocated abacavir; serious adverse events were most commonly lower respiratory tract 
infections or other speciﬁ c infections). HR=hazard ratio. NRTI=nucleoside reverse-transcriptase inhibitors. ART=antiretroviral treatment. *Stratiﬁ ed log-rank test. 
†Clinical grade 2 or greater, laboratory grade 3 (conﬁ rmed), laboratory grade 4 (all). ‡Includes grade 4 Stevens-Johnson syndrome from appendix p 7; adjudicated blind to 
actual NRTI received. Both children in the abacavir group continued abacavir without adverse eﬀ ects. See appendix p 11 for details of adjudicated relation to antiretrovirals. 
One additional grade 1 hypersensitivity reaction (not a primary endpoint) also occurred in the abacavir group: again the child continued abacavir without adverse eﬀ ects. 
§One cardiomyopathy (stavudine group) and one myopathy (abacavir group). ¶Clinical grade 3 or greater, laboratory grade 3 (conﬁ rmed), laboratory grade 4 (all). 
||See appendix p 4 for details of grade 3/4 adverse events and serious adverse events judged by the endpoint review committee as possibly having some relation to any of 
stavudine or zidovudine or abacavir (all events adjudicated for each drug blind to NRTI actually received, so toxicity from any of the three NRTIs could be attributed to each 
event). No grade 3/4 adverse events or serious adverse events were judged probably or deﬁ nitely related. **Not including changes for tuberculosis treatment (see main text); 
one toxicity substitution in child randomised to abacavir was actually from zidovudine to nevirapine for anaemia, following previous substitution of nevirapine to zidovudine 
(triple NRTI regimen) for tuberculosis treatment. Two stavudine and one zidovudine substitutions from nevirapine to lopinavir/ritonavir for rash/hypersensitivity reactions; 
all other substitutions were from stavudine or zidovudine. ††See appendix p 15 for relation between NRTIs and deaths. 
Table 2: Primary and secondary endpoints (time to event)
Stavudine 
change*
Zidovudine 
change*
Diﬀ erence† (95% CI) Abacavir 
change*
Diﬀ erence† (95% CI) p value‡ Diﬀ erence† (95% CI)
Growth
Weight-for-age 0·91 0·84 0·08 (–0·15 to 0·30) 0·75 –0·06 (–0·32 to 0·10) 0·21 –0·18 (–0·39 to 0·02)
Height-for-age 0·62 0·67 0·08 (–0·12 to 0·28) 0·61 0·02 (–0·21 to 0·24) 0·72 –0·06 (–0·27 to 0·15)
BMI-for-age 0·63 0·40 0·05 (–0·22 to 0·31) 0·42 –0·13 (–0·41 to 0·15) 0·40 –0·17 (–0·42 to 0·08)
Body circumference and skinfolds
Waist:hip ratio –0·03 –0·04 –0·01 (–0·02 to 0·00) –0·05 –0·01 (–0·03 to 0·01) 0·33 0·00 (–0·01 to 0·02)
Waist:arm ratio –0·03 –0·04 –0·04 (–0·10 to 0·00) –0·05 0·03 (–0·03 to 0·09) 0·13 0·07 (0·00 to 0·13)
Torso:arm skinfold ratio –0·02 –0·02 –0·00 (–0·04 to 0·03) –0·03 0·01 (–0·03 to 0·05) 0·87 0·01 (–0·03 to 0·05)
Sum of four skinfolds (mm) –1·88 –3·75 –1·13 (–2·86 to 0·60) –2·70 –0·28 (–2·07 to 1·52) 0·42 0·86 (–1·00 to 2·72)
*Mean change from baseline at 96 weeks. †Mean diﬀ erence in change in ﬁ rst 96 weeks from generalised estimating equation model. ‡Global test from generalised 
estimating equations with normally distributed errors and independent covariance. BMI=body-mass index.
 Table 3: Secondary endpoints (continuous)
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lower for their alternative second-line NRTI abacavir (64% 
and 89%, respectively; p=0·008 comparing susceptibility to 
the non-tenofovir second-line NRTI option across 
randomised groups).
Discussion
In the ﬁ rst African paediatric trial comparing three 
NRTIs coformulated in NNRTI/NRTI generic 
ﬁ xed-dose-combination paediatric tablets, dosed using 
WHO drug ratios and weight bands,2,5 we identiﬁ ed no 
major diﬀ erences in any adverse event or toxicity 
endpoint during nearly 2·5 years follow-up in ART-naive 
and ART-experienced children. First-line drug 
substitutions occurred in only 6% of children, with 
nearly one-third due to starting anti-tuberculosis 
treatment. ART-naive children had good clinical, 
immunological, and virological responses, regardless of 
backbone NRTI; CD4 cell count and virological 
responses were maintained among almost all ART-
experienced children. As expected, most deaths occurred 
early in children starting ART and only 1% switched to 
second-line therapy.
Paediatricians have long debated the relative advantages 
and disadvantages of diﬀ erent so-called backbone NRTIs 
combined with lamivudine, particularly because 
harmonising with adult tenofovir-based once-daily ART is 
not possible because of concerns about bone toxicity in 
growing children and absence of paediatric ﬁ xed-dose 
combinations or doses in those younger than 2 years. In 
the past decade, WHO guidelines have promoted 
paediatric ﬁ xed-dose combinations, ﬁ rst used in the 
CHAPAS-1 trial18 and licensed in 2007. However, preferred 
NRTI recommendations have changed from stavudine 
(2006) to zidovudine (20104) to abacavir (20135), based on 
minimal paediatric data and no randomised trials.
91% of children needing ART live in Africa, where 
genetic and environmental factors determine the relative 
eﬀ ect of diﬀ erent ART toxicity proﬁ les. We found no 
major diﬀ erences across randomised NRTIs in grade 2–4 
clinical or grade 3/4 laboratory adverse events, in either 
ART-naive or ART-experienced children. The only 
grade 3/4 event with marginally increased frequency was 
neutropenia in children allocated zidovudine; its 
signiﬁ cance is uncertain because African children have 
low neutrophil counts,19 and it rarely led to zidovudine 
substitution. As previously described,20 haemoglobin 
increased regardless of backbone NRTI, and severe 
anaemia occurred no more frequently in children who 
received zidovudine versus those who received stavudine 
or abacavir, suggesting HIV-related rather than drug-
related cause. However, although infrequent, drug 
substitution was more common in the zidovudine group 
than both other groups, as was also reported in the 
ARROW trial,20 mainly for anaemia. These combined trial 
results reassure clinicians that zidovudine substitution is 
rarely needed for anaemia among children on ART. 
However, an important caveat is that severe anaemia and 
neutropenia were an exclusion criteria in both trials; if 
anaemia is HIV related, initiating zidovudine might also 
lead to good haemoglobin responses in anaemic children, 
as observed here, but we did not assess this.
Clinical lipodystrophy was not recorded up to 3 years 
follow-up of children aged younger than 5 years at ART 
initiation. Absence of blinding cannot rule out 
ascertainment bias, but lack of signiﬁ cant diﬀ erences in 
Figure 3: Viral suppression in patients with less than 400 copies per mL (A) and viral less than 100 copies per mL (B)
Data are the absolute (95% CI) between-group diﬀ erences in overall suppression. ART=antiretroviral treatment. 
S=stavudine. Z=zidovudine. A=abacavir.
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body circumferences or skinfold thicknesses between 
NRTIs supports anecdotally reported rarity of 
lipodystrophy among young children, and suggests that 
longer-term consequences of stavudine exposure in 
young children are likely to be limited. We also found no 
evidence of a diﬀ erence between NRTIs in changes in 
lipids on ART. Nevertheless, lipodystrophy undoubtedly 
occurs in older children and adolescents; the only 
lipodystrophy noted during the trial was facial in two 
older ART-experienced children already taking stavudine 
for more than 2·5 years. For this reason, and despite 
little evidence of harm in young children, the WHO 2013 
recommendation that stavudine should be used only 
where other drugs are unavailable seems reasonable 
because it harmonises with adult and adolescent 
recommendations where evidence is strong. However, 
our results suggest that stavudine could be safely used 
for at least 2 years in young children (eg, with severe 
anaemia at ART initiation), if alternatives are not 
available, supporting WHO5 and the European Medicines 
Agency who recommended that stavudine for children 
should not be discontinued completely.
Despite no HLA-B5701 testing, no hypersensitivity 
reactions to abacavir were observed, in agreement with 
previous data reporting its rarity in African adults21 and 
children.10 The only three hypersensitivity reactions 
leading to a change in ART were substitutions from 
nevirapine to lopinavir plus ritonavir, albeit at a lower 
rate than in adults,22 consistent with previous paediatric 
reports.18 Reassuringly, and providing the ﬁ rst 
randomised data in children, a CHAPAS-3 substudy 
showed no diﬀ erence in cardiovascular measurements 
or biomarkers between randomised NRTI groups.23,24 
One limitation is that our trial recruited more ART-naive 
and fewer ART-experienced children than was planned, 
reducing the power to detect diﬀ erences between these 
subgroups, although no major interactions were 
identiﬁ ed.
When this trial was designed, the major questions 
related to toxicity proﬁ les of the three NRTIs, with 
concerns over the potency of abacavir12,13 only arising later. 
However, 478 children still provided good power to detect 
10–15% diﬀ erences in viral load suppression. CD4 
recovery and retrospectively assayed viral load suppression 
to less than 100 copies per mL, less than 400 copies 
per mL, or less than 1000 copies per mL (data not shown) 
did not diﬀ er by randomised NRTI (appendix p 16). 
Overall suppression was better in ART-experienced than 
in ART-naive children, as expected, because ART-
experienced children were suppressed at enrolment. 
Similarly to ARROW, there were no interactions 
suggesting diﬀ erences in viral load suppression by NRTIs 
by age (<3 years vs >3 years),20 and, also in agreement with 
other reports, there was no evidence that viral load 
suppression depended on intrauterine nevirapine 
exposure beyond infancy25 or NNRTI in children older 
than 3 years.26 Although many seminal trials have been 
done in HIV-infected children by the IMPAACT/PACTG 
group, their randomised comparisons of combination 
therapy have focused on the third (non-NRTI) drug (eg, 
PACTG-1060 nevirapine vs lopinavir plus ritonavir), older 
drugs (eg, PACTG-327 didanosine), or on receiving an 
additional NRTI (eg, PACTG-300). No IMPAACT/PACTG 
trial has directly compared abacavir, zidovudine, or 
stavudine head-to-head within combination therapy. Our 
results diﬀ er from the only previous randomised, smaller 
trial of zidovudine versus abacavir (PENTA-5), which 
showed virological superiority of abacavir versus 
zidovudine over 5 years in children in well-resourced 
settings.27,28 However, children received two NRTIs alone 
or with nelﬁ navir; with a potent third drug, as in 
CHAPAS-3, any superiority of abacavir over zidovudine 
could well be masked. Our results provide reassurance 
following recent observational analyses reporting poorer 
virological responses to abacavir versus stavudine in 
South African children.12,13 Possible explanations for the 
diﬀ erence include unmeasured confounding or drug–
drug interactions between abacavir and lopinavir plus 
ritonavir (the standard third drug in South Africa).29 Of 
interest, we did not ﬁ nd that abacavir did worse in 
children with higher viral loads in CHAPAS-3, but only 
24 ART-naive children were younger than 1 year, by 
contrast with the South African studies where many were 
younger than 1 year with high viral loads. The contribution 
of the ﬁ xed-dose combination rather than separate pills to 
virological success is diﬃ  cult to estimate, but cannot 
aﬀ ect our within-trial comparisons as all were using 
ﬁ xed-dose combinations.
Finally, these ﬁ rst randomised resistance data in 
African children on diﬀ erent NRTI plus NNRTI ﬁ rst-line 
ART reassuringly show that most children remained 
susceptible to second-line NRTIs over the medium term, 
regardless of initial NRTI. In particular, while those 
taking ﬁ rst-line zidovudine had signiﬁ cantly reduced 
susceptibility to abacavir second-line, those taking ﬁ rst-
line abacavir retained high susceptibility to zidovudine; 
both retained high susceptibility to tenofovir, increasingly 
used in children older than 10 years who weigh more 
than 35 kg.
At trial closure (before trial results were known), all 
carers and children were oﬀ ered continuing follow-up in 
the research trial centres (but without the transport 
refund provided by the trial) or moving to an ART 
programme site closer to where they lived. Children 
moving to ART programme sites were moved onto the 
ART regimen provided by the site (predominantly 
zidovudine at trial closure, abacavir for some Ugandan 
sites) to ensure that the ART programme site could 
continue to provide uninterrupted ART, in terms of drug 
provision and forecasting. Children staying at the 
research sites could continue their randomised regimen, 
because there was no reason to change drugs in children 
doing well and stable on a WHO recommended regimen, 
and being carefully followed for toxicity. However, 
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